Clinical Trials Browser

Phase 1 × Lymphoma, T-Cell, Cutaneous × Bendamustine Hydrochloride × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT02168140 2024-02-13

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1 Completed

16 enrolled

DermatologicLymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma